10-Q: TELA Bio Reports Q3 2024 Results: Revenue Growth Amidst Cost-Cutting Measures

Sentiment:

Quarterly Report 8 November 2024 4:05 PM

TELA Bio's Q3 2024 results show a 26% increase in revenue year-over-year, alongside a reduced net loss and the implementation of cost-cutting measures.

Capital raiseThe company completed an underwritten public offering of 14,670,000 shares of its common stock at a price of $2.25 per share.The offering included the exercise in full of the underwriters option to purchase additional shares.The company also issued pre-funded warrants to purchase 5,800,000 shares of common stock at a price of $2.2499 per pre-funded warrant.The offering resulted in gross proceeds of $46.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Better than expectedThe company's revenue growth of 26% in Q3 2024 and 25% for the first nine months of 2024 exceeded expectations.The net loss decreased by 5% in Q3 2024 and 15% for the first nine months of 2024, indicating better than expected financial performance.The company successfully completed a public offering in October 2024, raising $46.0 million in gross proceeds, which was better than expected.

Summary

TELA Bio reported a revenue of $19.0 million for the third quarter of 2024, a 26% increase compared to $15.1 million in the same period of 2023.
The company's net loss for the quarter was $10.4 million, a slight improvement from the $11.0 million loss in Q3 2023.
For the nine months ended September 30, 2024, revenue reached $51.7 million, a 25% increase from $41.5 million in the same period of 2023.
The net loss for the first nine months of 2024 was $28.6 million, compared to a $33.8 million loss in the same period of 2023, primarily due to a gain on the sale of a product line.
The company sold 4,767 units of OviTex and 1,293 units of OviTex PRS in Q3 2024, representing a 39% and 44% increase in unit sales volume respectively, compared to Q3 2023.
TELA Bio has implemented cost-cutting measures starting in the third quarter of 2024, which are expected to reduce operating expenses in future periods.
The company completed an underwritten public offering in October 2024, raising gross proceeds of $46.0 million.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While there is strong revenue growth and a reduction in net loss, the company is still operating at a loss and faces several risks. The successful capital raise and cost-cutting measures are positive signs, but the company's future performance is still uncertain.

Positives

Revenue growth of 26% in Q3 2024 and 25% for the first nine months of 2024 indicates strong market demand for TELA Bio's products.
The reduction in net loss, both for the quarter and the nine-month period, suggests improved financial performance.
The increase in unit sales volume for both OviTex and OviTex PRS demonstrates successful market penetration and adoption of the products.
The sale of the NIVIS product line generated a significant gain of $7.6 million, positively impacting the company's financials.
The successful public offering in October 2024 provides the company with additional capital to fund operations and growth initiatives.
Implementation of cost-cutting measures indicates a focus on financial discipline and efficiency.

Negatives

Despite revenue growth, the company continues to incur net losses, with a $10.4 million loss in Q3 2024 and a $28.6 million loss for the first nine months of 2024.
Gross margin decreased slightly to 68% for the nine months ended September 30, 2024, compared to 69% for the same period in 2023, due to higher excess and obsolete inventory charges.
The company experienced a decrease in average selling prices due to product mix, with smaller-sized units making up a larger share of sales.
External cybersecurity events and supply constraints for critical surgical supplies have negatively impacted procedural volumes and sales.
The company has an accumulated deficit of $349.5 million as of September 30, 2024.

Risks

The company's operations are subject to risks including product development, macroeconomic conditions, and the impact of public health crises.
There is uncertainty regarding the commercial acceptance of developed products and the impact of competing technologies.
The company is dependent on collaborative partners and faces risks related to patents and proprietary rights.
The company is subject to comprehensive government regulations and depends on key personnel.
The company's ability to maintain regulatory approval for its products and commercialize future products is uncertain.
The company faces risks related to decreasing selling prices, pricing pressures, and healthcare reform.
External cybersecurity events and supply constraints for critical surgical supplies may continue to impact procedural volumes and sales.
The company is exposed to the volatility of capital markets and adverse macroeconomic factors, including inflationary pressures and geopolitical tensions.
The company's ability to obtain additional capital to finance its planned operations is uncertain.

Future Outlook

TELA Bio expects to continue incurring losses for the foreseeable future, but anticipates that cost-cutting measures and revenue growth will improve financial performance. The company plans to continue investing in sales and marketing, research and development, and strategic partnerships to expand its product portfolio and market reach. The company believes that its existing cash resources, inclusive of the proceeds received in the underwritten public offering, will be sufficient to meet its capital requirements and fund its operations for at least the next 12 months.

Management Comments

Management is focused on driving operational leverage and efficiencies from the expanded commercial organization.
Management believes that genuine collaboration with surgeons and healthcare providers results in the development of new solutions that empower patient care.
Management is committed to delivering advanced technologies with a strong economic value proposition to assist surgeons and institutions in providing next-generation soft-tissue repair solutions to more patients worldwide.

Industry Context

TELA Bio operates in the competitive medical technology industry, specifically in the soft-tissue reconstruction market. The company's focus on combining biologic matrices and polymer materials positions it against larger competitors in the hernia repair and plastic surgery sectors. The company's growth is influenced by factors such as hospital procurement practices, patient needs, and reimbursement rates. The company is also impacted by broader industry trends such as cybersecurity events and supply chain disruptions.

Comparison to Industry Standards

TELA Bio's revenue growth of 25% year-over-year for the first nine months of 2024 is strong compared to the broader medical device industry, which typically sees single-digit growth rates.
The company's gross margin of 68% is within the typical range for medical device companies, but there is room for improvement.
The company's net losses are not uncommon for growth-stage medical device companies, which often prioritize investment in research and development and sales and marketing over short-term profitability.
Compared to companies like MiMedx, which acquired TELA Bio's NIVIS product line, TELA Bio is focused on a different segment of the market with its OviTex and OviTex PRS products.
The company's BRAVO study results, with a 2.6% recurrence rate for ventral hernias, are competitive with other hernia repair solutions.
The company's reliance on a single contract manufacturer, Aroa Biosurgery, is a risk, but the long-term supply agreement provides a competitive advantage.

Stakeholder Impact

Shareholders will be impacted by the recent public offering and the company's financial performance.
Employees may be impacted by the cost-cutting measures implemented in Q3 2024.
Customers will benefit from the company's continued investment in product development and innovation.
Suppliers will be impacted by the company's purchasing decisions and supply chain management.
Creditors will be impacted by the company's debt obligations and financial performance.

Next Steps

The company will continue to invest in sales and marketing initiatives to support growth in existing and new markets.
The company will continue to invest in research and development activities to develop new products and enhance existing ones.
The company will continue to assess strategic partnerships with medical device companies.
The company will continue to evaluate and finalize the clinical study protocol for the study of OviTex PRS in implant-based breast reconstruction.
The company anticipates additional FDA interactions related to the breast reconstruction study to support a pre-market application.

Key Dates

Date	Description
April 17, 2012	TELA Bio, Inc. was incorporated in the state of Delaware.
July 16, 2015	Date of the Second Amended and Restated License, Product Development and Supply Umbrella Agreement with Aroa Biosurgery Limited.
July 2016	TELA Bio first commercialized OviTex in the U.S.
February 2019	TELA Bio first commercialized OviTex in Europe.
April 2019	First OviTex PRS products received 510(k) clearance from the FDA.
May 2019	TELA Bio first commercialized OviTex PRS in the U.S.
November 2018	TELA Bio began commercializing OviTex LPR.
May 26, 2022	TELA Bio entered into the Credit and Security Agreement with MidCap Financial Trust.
October 2022	24-month results of the BRAVO study were published.
February 2023	TELA Bio launched two larger configurations of OviTex LPR.
March 2023	TELA Bio received 510(k) clearance for OviTex PRS Long-Term Resorbable device.
August 2023	TELA Bio announced the launch of OviTex PRS Long-Term Resorbable product configuration.
September 2023	TELA Bio entered into a distribution agreement with Advanced Medical Solutions Limited.
March 2024	TELA Bio sold its distribution rights for NIVIS to MiMedx Group, Inc. and announced the full commercial launch of LiquiFix in the U.S.
April 2024	TELA Bio launched OviTex IHR Reinforced Tissue Matrix and received clearance of a Special 510(k) related to minor changes to OviTex PRS devices.
August 1, 2024	Date of the Addendum to the Second Amended and Restated License, Product Development and Supply Umbrella Agreement with Aroa Biosurgery Limited.
September 30, 2024	End of the reporting period for the quarterly results.
October 2024	TELA Bio received approval from the FDA for its investigational device exemption application relating to the study of OviTex PRS in implant-based breast reconstruction and completed an underwritten public offering.
November 8, 2024	Date of the filing of the quarterly report.

Keywords

TELA Bio, OviTex, OviTex PRS, hernia repair, soft-tissue reconstruction, medical technology, surgical procedures, biologic matrices, plastic surgery, revenue, net loss, clinical study, medical devices

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.